Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

• Published in: The American heart journal Vol. 157; no. 3; pp. 562.e1 - 562.e9
• Main Authors: Varenhorst, Christoph, James, Stefan, Erlinge, David, Braun, Oscar O, Brandt, John T, Winters, Kenneth J, Jakubowski, Joseph A, Olofsson, Sylvia, Wallentin, Lars, Siegbahn, Agneta
• Format: Journal Article
• Language: English
• Published: United States 01.03.2009
• Subjects: Anticoagulants - administration & dosage; Aspirin - administration & dosage; Cardiac and Cardiovascular Systems; Clinical Medicine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring - instrumentation; Drug Therapy, Combination; Female; Humans; Kardiologi; Klinisk medicin; Male; Medical and Health Sciences; MEDICIN; Medicin och hälsovetenskap; MEDICINE; Optical Rotation; Phosphorylation; Piperazines - therapeutic use; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes - therapeutic use; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives

Variability in response to thienopyridines has led to the development of point-of-care devices to assess adenosine diphosphate (ADP)-induced platelet aggregation. These tests need to be evaluated in comparison to reference measurements of P2Y(12) function during different thienopyridine treatments....